The effect of labetalol and propranolol on the development of hypertension in spontaneously hypertensive rats. 1984

W S Gumułka, and Z Zalewska-Rutczyńska

The effect of long-term administration of propranolol (0.2 and 0.4 mg/kg-1 p.o.) and that of labetalol (2.0, 4.0 and 8.0 mg/kg-1 p.o. and 1 mg/kg-1 i.p.) on the development of hypertension was studied in female rats of SHR/N/Ibn strain. The experiment was started on 6-week-old animals. Rats received the tested drugs once daily between 11 and 12 o'clock. From the 29th day on (i.e. after the age of 10 weeks) the arterial blood pressure was measured bloodlessly twice weekly 2 hours before the daily dose of the drug. Labetalol given p.o. in a dose of 2 mg/kg-1 had no effect on the development of hypertension, while the doses 4.0 and 8.0 mg/kg-1 decreased the arterial pressure by about 4 kPa (30 mm Hg). After drug withdrawal a rapid rise was observed in the arterial pressure to values approaching the values recorded in control animals. In the animals receiving labetalol parenterally (1 mg/kg-1 i.p.) the blood pressure was significantly lower than in control rats. After drug withdrawal the blood pressure increased gradually, however, even on the 54th day of the experiment it was slightly below that in controls. Propranolol given orally in doses of 0.2 mg/kg-1 delayed the development of hypertension, while in the dose of 0.4 mg/kg-1 it prevented its development. After withdrawal of the lower drug dose the blood pressure remained for about 2 weeks at a level similar to the previous one, later on it increased steeply to the values observed in controls.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007741 Labetalol A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS. AH-5158,Albetol,Apo-Labetalol,Dilevalol,Labetalol Hydrochloride,Labetalol, (R,R)-Isomer,Labetolol,Normodyne,Presolol,R,R-Labetalol,SCH-19927,Trandate,AH 5158,AH5158,Apo Labetalol,ApoLabetalol,Hydrochloride, Labetalol,R,R Labetalol,SCH 19927,SCH19927
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D011918 Rats, Inbred SHR A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke. Rats, Spontaneously Hypertensive,Rats, SHR,Inbred SHR Rat,Inbred SHR Rats,Rat, Inbred SHR,Rat, SHR,Rat, Spontaneously Hypertensive,SHR Rat,SHR Rat, Inbred,SHR Rats,SHR Rats, Inbred,Spontaneously Hypertensive Rat,Spontaneously Hypertensive Rats
D004983 Ethanolamines AMINO ALCOHOLS containing the ETHANOLAMINE; (-NH2CH2CHOH) group and its derivatives. Aminoethanols
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

W S Gumułka, and Z Zalewska-Rutczyńska
September 1985, Japanese heart journal,
W S Gumułka, and Z Zalewska-Rutczyńska
October 1978, Canadian journal of physiology and pharmacology,
W S Gumułka, and Z Zalewska-Rutczyńska
October 1978, Japanese journal of pharmacology,
W S Gumułka, and Z Zalewska-Rutczyńska
August 1983, Klinische Monatsblatter fur Augenheilkunde,
W S Gumułka, and Z Zalewska-Rutczyńska
August 1982, Archives internationales de pharmacodynamie et de therapie,
W S Gumułka, and Z Zalewska-Rutczyńska
October 1997, Hypertension (Dallas, Tex. : 1979),
W S Gumułka, and Z Zalewska-Rutczyńska
February 2017, American journal of hypertension,
W S Gumułka, and Z Zalewska-Rutczyńska
January 1989, Magnesium,
W S Gumułka, and Z Zalewska-Rutczyńska
January 1988, European journal of pharmacology,
W S Gumułka, and Z Zalewska-Rutczyńska
July 2010, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!